Leap Therapeutics

Nov 13, 2023

•

Sep 30, 2023

Leap Therapeutics Q3 2023 Earnings Report

Reported financial results for the third quarter ended September 30, 2023.

Key Takeaways

Leap Therapeutics reported a net loss of $13.7 million for the third quarter of 2023, compared to a net loss of $15.1 million for the same period in 2022. The decrease in net loss was primarily due to decreased research and development expenses and increased interest income. Cash and cash equivalents totaled $80.7 million at September 30, 2023.

Advanced into Part B of the DeFianCe study evaluating DKN-01 plus bevacizumab and chemotherapy in second-line colorectal cancer.

Exceeded 20% overall response rate threshold in Part A of the DeFianCe study.

Plan to present new data from Part A of the DeFianCe study at a medical conference in January 2024.

Focused on executing the DisTinGuish study evaluating DKN-01 plus tislelizumab and chemotherapy in first-line gastric cancer.